Zai Lab Ltd. (ZLAB) expects to raise $100 million in an IPO on Wednesday, September 20th, IPO Scoop reports. The company will be issuing 5,900,000 shares at a price of $16.00-$18.00 per share.

The company has a market cap of $797.8 million.

J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

Zai Lab Ltd. provided the following description of their company for its IPO: “We are an innovative biopharmaceutical company based in Shanghai focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. We believe there exists a significant opportunity to build an organization that not only addresses such unmet needs but leverages underutilized resources in China to foster innovation. “.

Zai Lab Ltd. was founded in 2013 and has 50 employees. The company is located at 4560 Jinke Road, Bldg. 1, 4F, Pudong, Shanghai, 201210, China and can be reached via phone at +86 21 6163 2588 or on the web at http://www.zailaboratory.com.

Receive News & Ratings for Zai Lab Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.